Indrayani Biotech Limited has received formal listing approval from BSE Limited for equity shares issued through a rights issue. The approval was granted on November 06, 2026, and pertains to 83,64,036 equity shares with a face value of ₹10 each, issued as partly paid-up shares at ₹3.75 per share.
The shares bear distinctive numbers 1 to 8364036 and were issued on a rights basis. The company had submitted the required documents to BSE on November 03, 2026.
Trading permission for these securities is conditional upon the company submitting confirmation from depositories about the crediting of these shares to respective beneficiary accounts. Additionally, the company must apply for trading approval to the stock exchange within seven working days from the date of grant of listing approval, as mandated by SEBI circular no. SEBI/HO/CFD/PoD-2/P/CIR/2023/00094 dated June 21, 2023, and Schedule XIX of ICDR Regulations.
Non-compliance with the trading approval application requirement within the specified timeframe will attract fines as mentioned in the SEBI circular. The disclosure is made pursuant to SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 and Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The communication was signed by Swaminathan Govindarajan, Whole-time Director (DIN: 02481041) of Indrayani Biotech Limited, and the approval letter from BSE was signed by Nitinkumar Pujari, Assistant Vice President, and Akshata Mhatre, Deputy Manager. The company's registered address is Block 1, Module No. 33, 3rd Floor, SIDCO Electronic Complex, Thiru-Vi-Ka Industrial Estate, Guindy, Chennai, Tamil Nadu - 600032.